SHALBY145.25

Shalby Limited

· Pharma & Health
₹ CrorePeersGKSLGPTHEALTHINDRAMEDCOARTEMISMEDLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹1,562 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)2,685.161,256.992,120.102,120.10
Receivable Days (DSO)56.5458.8473.0473.04
Payable Days (DPO)1,479.23466.32723.75814.46
Cash Conversion Cycle (days)1,262.47849.511,469.391,378.68
Working Capital Turnover4.085.367.958.19
Asset Turnover0.580.640.620.62
Cash Conversion (CFO/Net Income)0.23-2.260.000.00
CFO/EBITDA0.11-0.030.000.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.